Wednesday, January 9, 2008

Bayhill Therapeutics Files For IPO

Palo Alto-based BayHill Therapeutics, a firm that develops biopharmaceuticals for the treatment of autoimmune diseases, filed for an IPO today. According to a filing with the SEC, Bayhill is looking to raise up to $86.25M in an IPO on the Nasdaq Global Market as BHTX. The firm's IPO is being underwritten by Pacific Growth Equities, Lazard Capital Markets, Merriman Curhan Ford & Co., and Punk, Ziegel & Company. Bayhill is venture backed by US Venture PArtners, Morgenthaler Partners, De Novo Ventures, CMEA Ventures, Eli Lilly, Latterell Venture Partners, and Montreux Equity Partners.